🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Baltic Countries.

Recruitingn/aAges 18 Years - anyAllPomeranian Medical University Szczecin
NCT06809101 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Introduction: The number of diagnosed cancers is systematically increasing every year. Cancer patients need to undergo regular blood tests to monitor safety and eligibility for treatment. In case of poor blood results, the chemotherapy session must be omitted. For patients living far from the center, this means unnecessary travel with involvement of helpers, additional costs, increased potential of hospital acquired infections, and frustration associated with missed opportunity for treatment. Aims: The primary aim of this study is to gain knowledge about successful implementation of remote, home monitoring of complete blood count to cancer patients during and after systemic treatment for cancer. The secondary aim of the AMBeR collective study protocol is to pilot new technology, gain more context around future investigations and verify costs and changes in patient treatment pathways.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * legally competent patients * aged 18 or older * diagnosed with cancer (ICD-10: C00\* - C97\*) * enrolled at the Department of Oncology/Hematology for outpatients * participants who are willing and able to give informed consent for participation in the study * participants should receive chemotherapy in Daily Chemotherapy Unit and be within 4 weeks of chemotherapy initiation, and the expected duration of chemotherapy should be at least 12 weeks from inclusion Exclusion Criteria: * inability to give informed consent due to mental capacity or language barrier * patient unable or unlikely to be able to perform fine manipulation required to use lancet or cartridge to obtain capillary blood sample and result * known bleeding disorder * bad circulation preventing the patient from getting enough blood drops to perform the test
💊

What it tests

  • Not listed
📍

Where

5 sites
Department of Oncology, Zealand University Hospital
Næstved, Denmark
Clinic and Polyclinic for Internal Medicine C, Hematology and Oncology, Palliative Care Unit, University Medical Center
Greifswald, Germany
Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine, University Medical Center
Rostock, Germany
Department of Oncology and Radiotherapy, University Clinical Center of Gdańsk,
Gdansk, Poland
Department of Hematology and Transplantology
Szczecin, Poland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy